Stock listing
OTC:ORGS Orgenesis Inc. Stock
Follow Orgenesis Inc. into a list and get an email when it puts out news.
Share price · OTC:ORGS
$0.02 USD +0.02 (+900.0%)
Close on Nov 18, 2026
Past year -95.0% · daily closes, Jul 21, 2026 – Nov 18, 2026, adjusted for splits- Day range
- $0.02 – $0.315 USDNov 18, 2026
- Volume
- 250 sharesNov 18, 2026
- Market cap
- —Left out: price × shares is far from the company's reported size
- Traded on an average day
- $167 USDMedian day 101 shares · 5 days with no trades · last 3 months, Aug 18, 2026 – Nov 18, 2026
Daily closes
Last 3 months, Aug 18, 2026 – Nov 18, 2026 · OTC:ORGS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|
| $0.02 | +0.018 | +900.0% | $0.315 | $0.315 | $0.02 | 250 |
|---|
| $0.0020 | -0.328 | -99.4% | $0.30 | $0.33 | $0.0004 | 1,975 |
|---|
| $0.33 | -0.045 | -12.0% | $0.30 | $0.33 | $0.30 | 1,262 |
|---|
| $0.375 | +0.075 | +25.0% | $0.375 | $0.375 | $0.375 | 110 |
|---|
| $0.30 | 0.00 | 0.0% | $0.30 | $0.30 | $0.30 | 100 |
|---|
| $0.30 | 0.00 | 0.0% | $0.346 | $0.346 | $0.01 | 429 |
|---|
| $0.30 | -0.05 | -14.3% | $0.30 | $0.30 | $0.30 | 100 |
|---|
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.35 | 100 |
|---|
| $0.35 | -0.05 | -12.5% | $0.35 | $0.35 | $0.35 | 100 |
|---|
| $0.40 | -0.09 | -18.4% | $0.49 | $0.49 | $0.037 | 900 |
|---|
| $0.49 | +0.14 | +40.0% | $0.49 | $0.49 | $0.49 | 100 |
|---|
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.35 | 0 |
|---|
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.35 | 0 |
|---|
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.35 | 0 |
|---|
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.35 | 0 |
|---|
| $0.35 | -0.20 | -36.4% | $0.35 | $0.35 | $0.35 | 200 |
|---|
| $0.55 | -0.03 | -5.2% | $0.55 | $0.55 | $0.55 | 100 |
|---|
| $0.58 | +0.03 | +5.5% | $0.067 | $0.58 | $0.067 | 357 |
|---|
| $0.55 | 0.00 | 0.0% | $0.55 | $0.55 | $0.55 | 100 |
|---|
| $0.55 | -0.03 | -5.2% | $0.55 | $0.55 | $0.55 | 100 |
|---|
| $0.58 | -0.088 | -13.1% | $0.58 | $0.58 | $0.58 | 150 |
|---|
| $0.668 | +0.167 | +33.5% | $0.668 | $0.668 | $0.668 | 100 |
|---|
| $0.50 | -0.08 | -13.8% | $0.50 | $0.50 | $0.50 | 140 |
|---|
| $0.58 | -0.01 | -1.7% | $0.58 | $0.58 | $0.58 | 100 |
|---|
| $0.59 | 0.00 | 0.0% | $0.59 | $0.59 | $0.59 | 100 |
|---|
| $0.59 | +0.168 | +39.7% | $0.59 | $0.59 | $0.59 | 100 |
|---|
| $0.422 | -0.168 | -28.4% | $0.41 | $0.422 | $0.41 | 2,838 |
|---|
| $0.59 | -0.079 | -11.9% | $0.59 | $0.59 | $0.59 | 100 |
|---|
| $0.669 | +0.079 | +13.5% | $0.669 | $0.669 | $0.669 | 100 |
|---|
| $0.59 | +0.24 | +68.6% | $0.59 | $0.59 | $0.59 | 102 |
|---|
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.033 | 400 |
|---|
| $0.35 | -0.10 | -22.2% | $0.35 | $0.35 | $0.35 | 100 |
|---|
| $0.45 | +0.038 | +9.1% | $0.45 | $0.45 | $0.45 | 102 |
|---|
| $0.412 | +0.062 | +17.8% | $0.05 | $0.412 | $0.05 | 1,127 |
|---|
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.35 | 100 |
|---|
| $0.35 | 0.00 | 0.0% | $0.57 | $0.57 | $0.033 | 8,530 |
|---|
| $0.35 | +0.24 | +218.2% | $0.35 | $0.35 | $0.35 | 100 |
|---|
| $0.11 | +0.077 | +236.4% | $0.11 | $0.59 | $0.11 | 286 |
|---|
| $0.033 | 0.00 | 0.0% | $0.033 | $0.37 | $0.033 | 2,767 |
|---|
| $0.033 | -0.067 | -67.3% | $0.79 | $0.79 | $0.033 | 1,100 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 0 |
|---|
| $0.10 | +0.067 | +205.8% | $0.10 | $0.10 | $0.10 | 239 |
|---|
| $0.033 | -0.267 | -89.1% | $0.595 | $0.595 | $0.033 | 300 |
|---|
| $0.30 | -0.05 | -14.3% | $0.30 | $0.30 | $0.30 | 115 |
|---|
Splits
3 splits since 2011 · OTC:ORGS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|
| 1-for-10 | Consolidation |
|---|
| 1-for-12 | Consolidation |
|---|
| 35-for-1 | Split |
|---|
- Ticker
- OTC:ORGS
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Orgenesis Inc. on 6ix
- Calls
- 9 calls with a replay · 9 with a transcript · latest Aug 11, 2023
- Decks
- 11 decks · latest Aug 29, 2024
Valuation
price Nov 18, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 1.54
Team and board
| Officer | Role |
|---|
| Vered Caplan | Chief Executive Officer of Orgenesis Inc. |
|---|
| Victor Miller | Chief Financial Officer of Orgenesis |
|---|
Events
Calls
| Call | When | Status |
|---|
| Orgenesis (OTC:ORGS) Q2 2023 Earnings Call | Fri, Aug 11, 2023 · 8:00 AM ET | Replay |
|---|
| Orgenesis (OTC:ORGS) Q4 2022 Earnings Call | Tue, Mar 21, 2023 · 11:00 AM ET | Replay |
|---|
| Orgenesis (OTC:ORGS) Q3 2022 Earnings Call | Fri, Nov 11, 2022 · 8:00 AM ET | Replay |
|---|
| Orgenesis (OTC:ORGS) Q2 2022 Earnings Call | Tue, Aug 16, 2022 · 11:00 AM ET | Replay |
|---|
| Orgenesis (OTC:ORGS) Q4 2021 Earnings Call | Wed, Mar 30, 2022 · 12:00 PM ET | Replay |
|---|
| Orgenesis (OTC:ORGS) Q3 2021 Earnings Call | Thu, Nov 04, 2021 · 8:30 AM ET | Replay |
|---|
| Orgenesis (OTC:ORGS) Q2 2021 Earnings Call | Thu, Aug 05, 2021 · 8:30 AM ET | Replay |
|---|
| Orgenesis (OTC:ORGS) Q1 2021 Earnings Call | Fri, May 07, 2021 · 8:30 AM ET | Replay |
|---|
| Orgenesis (OTC:ORGS) Q4 2020 Earnings Call | Tue, Mar 09, 2021 · 8:30 AM ET | Replay |
|---|
Results days
| Quarter | Results |
|---|
| Q3 2024 | Nov 11, 2024 · Before open |
|---|
| Q2 2024 | Aug 8, 2024 · After close |
|---|
| Q1 2024 | May 20, 2024 · After close |
|---|
| Q3 2023 | Nov 13, 2023 · After close |
|---|
| Q2 2023 | Aug 10, 2023 · After close |
|---|
| Q1 2023 | May 10, 2023 · After close |
|---|
| Q4 2022 | Mar 22, 2023 · After close |
|---|
| Q3 2022 | Nov 10, 2022 · After close |
|---|
| Q2 2022 | Aug 15, 2022 · After close |
|---|
| Q1 2022 | May 23, 2022 · After close |
|---|
All 15 quarters
| Quarter | Results |
|---|
| Q4 2021 | Mar 30, 2022 · Before open |
|---|
| Q3 2021 | Nov 4, 2021 · After close |
|---|
| Q2 2021 | Aug 5, 2021 · After close |
|---|
| Q1 2021 | May 6, 2021 · After close |
|---|
| Q4 2020 | Mar 9, 2021 · After close |
|---|
Open Events
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2018 | FY2017 | FY2016 |
|---|
| Revenue | 1.03M | 530.0K | 36.0M | 35.5M | 7.65M | 33.3M | 18.7M | 18.7M | 10.1M | 6.40M |
|---|
| Cost of revenue | 9.51M | 6.25M | 20.4M | 28.2M | 31.1M | 18.1M | 10.7M | 10.7M | 6.81M | 7.66M |
|---|
| Gross profit | -8.47M | -5.72M | 15.6M | 7.34M | -23.4M | 15.1M | 7.96M | 7.96M | 3.28M | -1.26M |
|---|
| Research and development | 3.84M | 11.1M | 6.01M | 36.6M | 84.0M | 12.5M | 6.46M | 6.46M | 2.48M | 2.16M |
|---|
| Selling, general and administrative | 12.9M | 34.6M | 16.2M | 15.4M | 19.4M | 25.3M | 16.6M | 16.6M | 10.7M | 6.45M |
|---|
| Operating income | -26.1M | -53.6M | -7.54M | -16.8M | -95.8M | -24.6M | -14.7M | -14.7M | -11.2M | 11.3M |
|---|
| Depreciation and amortization | 2.09M | 1.56M | 1.98M | 1.86M | 1.44M | 3.81M | 2.62M | 2.62M | 2.60M | 2.92M |
|---|
| EBITDA | -24.0M | -52.1M | -5.56M | -14.9M | -94.3M | -20.8M | -12.0M | -12.0M | -8.63M | 14.2M |
|---|
| Interest expense | 3.74M | 2.17M | 1.82M | 369.0K | 1.09M | 461.0K | 2.75M | 2.75M | 1.23M | 689.0K |
|---|
| Income before tax | -48.9M | -64.4M | -12.0M | -18.0M | -96.7M | -25.5M | -17.8M | -17.8M | -13.7M | -10.7M |
|---|
| Income tax | | 473.0K | 209.0K | 108.0K | -1.61M | 563.0K | 1.34M | 1.34M | -1.31M | -1.55M |
|---|
| Net income | -48.2M | -55.4M | -14.9M | -18.1M | -95.8M | -26.0M | -18.3M | -18.3M | -12.4M | -9.19M |
|---|
| Earnings per share, basic | -9.31 | -1.91 | -0.59 | -0.74 | -4.49 | -1.64 | -1.37 | -1.37 | -1.27 | -1.08 |
|---|
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2018 | FY2017 | FY2016 |
|---|
| Cash and equivalents | 78.0K | 837.0K | 5.31M | 5.47M | 44.9M | 11.4M | 16.1M | 16.1M | 3.52M | 891.0K |
|---|
| Short-term investments | | | | 152.0K | | | | | | |
|---|
| Receivables | 40.0K | 2.56M | 39.8M | 19.7M | 3.25M | 2.04M | 11.2M | 11.2M | 2.21M | 2.13M |
|---|
| Inventory | 0 | 34.0K | 120.0K | 118.0K | 185.0K | 2.04M | 1.74M | 1.74M | 725.0K | 400.0K |
|---|
| Current assets | 761.0K | 4.08M | 46.3M | 25.8M | 50.1M | 26.0M | 30.3M | 30.3M | 7.29M | 4.21M |
|---|
| Property, plant and equipment | | | | 5.11M | 4.27M | 3.03M | 12.5M | 11.9M | 5.10M | 4.57M |
|---|
| Goodwill | 0 | 1.21M | 8.19M | 8.40M | 8.74M | 14.9M | 15.2M | 15.2M | 10.7M | 9.58M |
|---|
| Total assets | 1.35M | 14.6M | 90.9M | 59.8M | 77.7M | 92.5M | 75.4M | 75.4M | 39.9M | 33.5M |
|---|
| Accounts payable | 10.4M | 6.58M | 4.43M | 5.24M | 8.65M | 5.55M | 3.80M | 3.80M | 3.91M | 4.55M |
|---|
| Current liabilities | 26.9M | 16.4M | 15.9M | 15.4M | 16.3M | 31.6M | 17.1M | 17.1M | 16.9M | 14.6M |
|---|
| Long-term debt | 8.47M | 19.0M | 13.3M | 4.85M | 7.26M | 13.4M | 2.85M | 2.70M | 4.53M | 4.35M |
|---|
| Total debt | | 22.6M | 20.3M | 11.8M | 12.9M | 24.8M | 3.73M | 3.73M | 7.69M | 9.84M |
|---|
| Total liabilities | 38.9M | 35.5M | 31.7M | 21.2M | 25.0M | 86.4M | 46.8M | 46.8M | 25.7M | 22.9M |
|---|
| Shareholders' equity | -37.5M | -21.0M | 27.6M | 38.5M | 52.6M | 5.48M | 28.4M | 28.6M | 14.1M | 10.6M |
|---|
| Shares outstanding | 5.17M | 29.0M | 25.1M | 24.3M | 21.3M | 15.9M | 13.4M | 13.4M | 9.71M | 8.52M |
|---|
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2018 | FY2017 | FY2016 |
|---|
| Cash from operations | -17.1M | -14.8M | -24.9M | -26.9M | -78.0M | -13.2M | -15.7M | -15.7M | -3.83M | -3.78M |
|---|
| Capital spending | -263.0K | -2.10M | -12.4M | -7.87M | -1.52M | -12.1M | -5.56M | -5.56M | -975.0K | -1.43M |
|---|
| Free cash flow | -17.3M | -16.9M | -37.3M | -34.7M | -79.6M | -25.3M | -21.2M | -21.2M | -4.81M | -5.21M |
|---|
| Cash from investing | | -3.71M | -14.1M | -12.4M | 105.6M | -13.8M | -6.27M | -6.27M | -3.40M | -1.54M |
|---|
| Cash from financing | 16.0M | 13.6M | 39.6M | -106.0K | 5.88M | 24.1M | 35.1M | 35.1M | 8.37M | 2.12M |
|---|
| Dividends paid | | | | -106.0K | | | | | | |
|---|
| Share buybacks | | | -107.0K | -1.02M | -250.0K | 13.2M | | 17.4M | 5.30M | 1.49M |
|---|
| Change in cash | -752.0K | -4.89M | 395.0K | -39.6M | 33.5M | -2.96M | 12.9M | 12.9M | 2.63M | -3.28M |
|---|
Open Financials
Cap table
Built by 6ix from Orgenesis Inc.’s releases
- Common shares
- 9,799,538
- Fully diluted
- 9,799,538
Fully diluted
| Line | Shares |
|---|
| Common shares | 9,799,538 |
|---|
Share count over time
| Count | Shares |
|---|
| Nov 22, 2026 | 9,799,538 |
|---|
Open Cap table
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|
David SidranskyOther companies: Ascentage Pharma Group International (Independent non-executive Director · Since at least Mar 18, 2026); Galmed Pharmaceuticals Ltd. (Lead Independent Director · Since at least Mar 18, 2026); Champions Oncology, Inc. (Lead Director · Since at least Aug 28, 2009); Cactus Acquisition Corp. 1 Limited (Director · Oct 28, 2021 – Oct 28, 2021 · Past); Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Akari Therapeutics PLC (Director · Jan 1, 2015 – Jan 1, 2015 · Past); Immune Pharmaceuticals Inc (Director · Oct 10, 2013 – Jan 8, 2015 · Past); Advaxis Inc (Director · Jul 16, 2013 – May 4, 2020 · Past); Zila Inc (Director · Oct 24, 2006 – Jan 9, 2007 · Past) | Director · Oct 22, 2018 – Dec 20, 2023 · Past |
|---|
| Elliot Maltz | Chief Financial Officer · Sep 1, 2023 – Sep 4, 2023 · Past |
|---|
| Adam Pelavin | Director · Oct 28, 2024 – Dec 12, 2024 · Past |
|---|
| Ashish Nanda | Director · Dec 23, 2022 – Dec 12, 2024 · Past |
|---|
| Chris Georges Frans Buyse | Director · Mar 2, 2015 – Mar 2, 2015 · Past |
|---|
| Denis Bedoret | See Remarks · May 14, 2018 – Mar 5, 2019 · Past |
|---|
| Dov Weinberg | CFO, Secretary & Treasurer · Feb 2, 2012 – Feb 2, 2012 · Past |
|---|
| Guy Yachin | Director · Oct 22, 2018 – Dec 20, 2023 · Past |
|---|
| Itzhak Vider | Director · Jul 8, 2024 – Dec 12, 2024 · Past |
|---|
| Jacob Benairie | President & CEO · Feb 2, 2012 – Feb 2, 2012 · Past |
|---|
All 21 people
| Person | Seat |
|---|
| Jagannathan Bhalaji | Director · Oct 28, 2024 – Dec 12, 2024 · Past |
|---|
| Kunik Efrat Assa | Chief Development Officer · Dec 15, 2021 – Jun 14, 2022 · Past |
|---|
| Mario Philips | Director · Jan 9, 2020 – Dec 20, 2023 · Past |
|---|
| Mark Goodman | Director · Jun 27, 2024 – Jun 27, 2024 · Past |
|---|
| Neil Reithinger | CFO, Treasurer and Secretary · Mar 5, 2019 – Jun 14, 2022 · Past |
|---|
| Santhosh Nagaraj | Director · Oct 28, 2024 – Dec 12, 2024 · Past |
|---|
| Sarah Ferber | Chief Scientific Officer · Feb 2, 2012 – Mar 19, 2020 · Past |
|---|
| Sav DiPasquale | President and CEO · Dec 17, 2012 – Dec 17, 2012 · Past |
|---|
| Vered Caplan | Chief Executive Officer of Orgenesis Inc. · Since at least Nov 30, 2016 |
|---|
| Victor Miller | Chief Financial Officer of Orgenesis · Since at least Jan 2, 2024 |
|---|
| Yaron Adler | Director · Dec 31, 2021 – Dec 12, 2024 · Past |
|---|
Open People
Log in to ask 6ix AI your own questions about Orgenesis Inc.